Department of Medicine

HemHub Seminar Series


Seminar Series Schedule 2021-2022


Held virtually via zoom: Noon - 1 p.m. (CST)

Zoom Link 
Meeting ID:  387 923 767
Passcode:  831342

Date Speaker Title/Presentation
Aug. 23,2021 Lucy A. Godley, M.D., Ph.D.
Hospira Foundation Professor of Medicine and Human Genetics
University of Chicago Medicine
Germline predisposition for myelodysplasia and acute myelogenous leukemia
View Presentation
(BCM login required)
Sept. 20, 2021

Ann Mullally, M.D.
Dana-Farber/Brigham and Women’s Cancer Center
Harvard Medical School

Towards Rationally Designed Approaches to Treat Pre-clinical and Overt MPN
View Presentation
(BCM login required)
Oct. 4, 2021

Ola Landgren, M.D., Ph.D.
UHealth, Sylvester Comprehensive Cancer Center, University of Miami Health System  

Advances in therapy of relapsed/refractory myeloma
View Presentation
(BCM login required)
Oct. 18, 2021

Justin Lathia, Ph.D.
Cleveland Clinic, Learner Research Institute

Cancer stem cell-immune system interactions drive disease progression
View Presentation
(BCM login required)

Nov. 1, 2021

Robert Kridel, M.D., M.P.H., Ph.D.
University of Toronto

Off the shelf CAR T Cells in B Cell Malignancies
Nov. 15, 2021

Charlotte Graham, Ph.D.
Kings College Hospital

Off the shelf CAR T Cells in B Cell Malignancies
Nov. 29, 2021

Enrico Derenzini, M.D., Ph.D.
IEO European Institute of Oncology

Exploring the DNA damage response as a therapeutic target in DLBCL?
Dec. 13, 2021

Navdeep S. Chandel, Ph.D.
Feinberg School of Medicine, Northwestern University

Unraveling Cancer cell Metabolism
Dec. 27, 2021 TBD  
Jan. 10, 2022

Eirini Papapetrou, M.D., Ph.D.
Icahn School of Medicine at Mount Sinai

Identifying novel AML targets
Jan. 24, 2022

Prof. Jesus M Hernandez M.D., Ph.D.
Department of Medicine, University of Salamanca, Spain

MDS to AML transition
Feb. 7, 2022

Siddhartha Jaiswal, M.D., Ph.D.
Stanford University

Clonogenic Mechanism Responsible for Hemopoietic Malignancy Transformation
Feb. 21, 2022 TBD  
March 7, 2022 Christopher Hourigan, M.D., D.Phil
National Institutes of Health
Advances in AML Meassurable residual disease